Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asundexian versus apixaban in atrial fibrillation for prevention of stroke or systemic embolism
2022-000758-28Phase 3Active
- Sponsor
- Bayer
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Asundexian arm with Apixaban arm (2 arms). Started Oct 2022; status: active.
02
Drugs
asundexianapixaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2022-000758-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000758-28.